ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.56 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.74 per share a year ago. These figures are adjusted for nonrecurring items. A quarter ago, it was expected that this company would post a loss of $0.47 per share when it actually produced a loss of $1.03, delivering a surprise of -119.15%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. ADC Therapeutics, which belongs to ...